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The clinical spectrum for celiac disease (CD) is broad and includes cases with either typical (intestinal) or atypical
(extraintestinal) features, often making the diagnosis of CD very difficult.
We describe the case of a girl presenting with stunted growth and malnourishment. She was evaluated at 14
months for decreased growth rate without any signs of gastrointestinal, renal or endocrine disorders. She was
evaluated for CD, but resulted negative for anti-tTG antibodies.
At the age of 4.1 years, she exhibited basal dental enamel hypoplasia, iron deficiency anaemia despite repeated iron
supplementation, with persistent reduced height (−2.79 SDS), BMI (−0.76 SDS), growth velocity (−1.79 SDS) and delayed
bone age (1.5 year). The CD screening was repeated and very high anti-tTG-IgA (128 IU/ml, normal values < 7 IU/ml) and
anti-tTG-IgG (77 IU/ml, normal values < 7 IU/ml) values were found. HLA genotyping revealed an HLA DQ2 haplotype.
A duodenal biopsy revealed severe villous atrophy with crypt hyperplasia and increased intraepithelial lymphocytes
(> 40 IELs/100 epithelial cells) confirming the diagnosis of CD. A gluten-free diet was started and after only four months,
her growth velocity increased from 4.83 cm/year (−1.79 SDS) to 6.53 cm/year (−0.15 SDS).
In conclusion, we report the development of a positive serology for CD in an asymptomatic child with growth
retardation, who previously was investigated for CD and resulted negative. Therefore, when faced with retarded growth
in young patients, after excluding other malabsorption conditions and even when CD serological markers are negative,
the paediatric endocrinologist should request HLA genotyping, before the intestinal biopsy, in order to check for the
presence of risk alleles.
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Celiac disease (CD) is an immune-mediated disease which
is triggered by the ingestion of gliadin and other prola-
mines which are toxic in genetically susceptible subjects.
The genetic risk factors for CD have been well character-
ized. In fact, more than 90% of patients share the major
histocompatibility complex II class human leukocyte anti-
gen (HLA)-DQ2 haplotype and most of the remaining
subjects carry HLA-DQ8 [1,2]. Subjects negative for both
HLA-DQ2 and -DQ8 are very unlikely to suffer from CD.
Therefore, HLA genotyping is an important as exam for
first degree relatives or as a supporting test when biopsy
is excluded due to its invasive nature in symptomatic
subjects with high antibody levels [3].* Correspondence: mauro.bozzola@unipv.it
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stated.Occasionally, the diagnosis of CD can be difficult in
patients in whom serological markers are absent. As sug-
gested by the new ESPGHAN guidelines, if there is a
strong suspicion of CD, despite a negative serology, a
small bowel biopsy has to be performed [3].
Here, we describe an asymptomatic child with stunted
growth and negative serology, in whom CD was not di-
agnosed at the first evaluation, but later during the
follow-up when she became seropositive for CD.Case presentation
A 4.1-year-old girl was referred to our department for fail-
ure to thrive and anorexia. She was born at term after an
uneventful pregnancy with a weight of 3,230 g, a length of
52 cm and head circumference of 34.5 cm. The perinatal
period was normal and her Apgar score was 9 at 5 min.
She received formula from birth. Gluten was included for
the first time at the age of seven months, without anyl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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girl was 163 cm (0.13 SDS). Both parents are healthy and
unrelated, and had normal development during puberty.
From the age of six months, she showed a progressive
reduction in growth rate, both for weight and height,
and at the age of 14 months, she was evaluated at an-
other centre and showed short stature (cm 69.9, -2.19
standard score deviation, SDS) (Figure 1) with adequate
weight (7,520 Kg, body mass index (BMI) -0.45 SDS),
free thyroxin (FT4) and thyroid-stimulating hormone
(TSH) were within the normal range. Furthermore,
serum anti-transglutaminase (anti-tTG) antibodies were
negative (IgA-tTG 1.7 IU/ml and IgG-tTG 7.2 IU/ml;
normal values <7 IU/ml) with normal for age circulating
IgA values (38 mg/100 ml; normal values: 37–257 ng/ml).
She exhibited iron deficiency anaemia, but the sweat test
(Na+ 16 mEq/l and Cl- 13 mEq/l; normal values: Na+ and
Cl- <40 mEq/l) and peripheral T and B cell assessment
resulted normal. No abnormalities of the kidneys were
detected by ultrasound and no gastrointestinal disorders
were reported.gluten-free diet
Figure 1 Height curve of the subject. The arrow indicates the start of thAt the moment of our evaluation, at the age of 4.1 years,
physical examination revealed only basal dental enamel
hypoplasia. She showed a height of 89.5 cm (−2.79 SDS)
(Figure 1), a weight of 12,5 Kg (BMI −0.76 SDS), a delayed
bone age of 1.5 years, and a growth velocity during the
last year of 4.83 cm/year (−1.79 SDS). Iron deficiency
anaemia persisted despite cyclically repeated iron sup-
plementation. The screening for CD was repeated and
very high IgA -tTG (128 IU/ml) and IgG-tTG (77 IU/
ml) values were observed. These data were highly sug-
gestive of CD. HLA genotyping revealed DQA1*02:01,
05:05 and DQB1 *02:02, 03:01 haplotypes (i.e. HLA DQ2
haplotype). A duodenal biopsy revealed severe villous
atrophy (Marsh 3c) with crypt hyperplasia and increased
intraepithelial lymphocytes (> 40 IELs/100 epithelial cells)
confirming the diagnosis of CD. A gluten-free diet was
started and after only four months her growth velocity in-
creased from 4.83 cm/year (−1.79 SDS) to 6.53 cm/year
(−0.15 SDS).
HLA genotyping in first-degree relatives revealed
DQA1*05:01, 05:05 and DQB1*02:01, 03:01 in her oldere gluten-free diet.
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his diet includes gluten and he repeats CD serology test-
ing every three years.
Discussion
Celiac disease is not simply a gastrointestinal condition, but
an immune-mediated systemic disorder, strongly dependent
on HLA-DQ2 and DQ8 haplotypes. At present, diagnosing
CD is often difficult, due to the reduced prevalence of
the classical form with gastrointestinal symptoms and
the increased prevalence of atypical forms [4]. Clinical
suspicion should be supported by positive serological
tests and diagnosis requires typical histopathological
findings with a biopsy of the small intestine, especially
when the patient is asymptomatic [3]. It is important to
stress that early diagnosis of CD with prompt initiation
of a gluten-free diet can decrease the potential risk of
both adenocarcinoma and lymphoma, which occurs
more frequently in untreated celiac patients than in the
general population [5].
This report emphasizes the difficulty of diagnosing CD
in asymptomatic patients with a negative serology who
exhibit only stunted growth. In fact, when this patient
was first evaluated, she resulted negative for anti-tTG,
her only symptom was progressive growth failure.
The negative serology observed in our patient at the
14th month of life could be related to the lower sensitivity
of anti-tTG antibodies in children younger than two years,
as recently described by Maglio et al. [6]. We did not
measure antibodies against native gliadin (AGA) which is
indicated in children up to two years old [7]. However, a
recent study suggested that IgA-anti-tTG results are more
reliable than AGA, also in younger children [8].
Then, interestingly after about a three year-follow-up,
high serum levels of anti-tTG unexpectedly appeared in
the absence of typical CD gastrointestinal features. Fur-
thermore, the HLA genotyping showed one haplotype
linked to CD susceptibility. Interestingly, a different
haplotype linked to CD susceptibility was found in her
asymptomatic older brother who currently exhibits a
negative serology. We may speculate that this difference
is due to a different gene dose effect of the allele that
contributes to the development of CD. In fact, in several
studies the risk of CD has been found to be significantly
greater in subjects homozygous for the DQB1*0201 al-
lele than in subjects heterozygous for the same allele
[9,10]. However, both subjects have DQ2 haplotype in
the heterozygous state (although with different risk al-
leles). On the other hand, conflicting data have been
published on the gene dose effect and the number of
risk alleles on the age of CD diagnosis and severity of
symptoms [11-13].
It is well known that the sensitivity and specificity of
HLA genotyping are sufficiently high to exclude CD onlywhen all risk alleles including DQ2 and DQ8 are absent.
The ESPGHAN guidelines for the diagnosis and manage-
ment of CD in children suggest HLA genotyping in asymp-
tomatic children with associated conditions and negative
serology. When HLA DQ2/DQ8 is positive, surveillance
should continue and serology for CD should be repeated
every three years [3]. On the contrary, when HLA DQ2/
DQ8 is negative, the development of CD is highly unlikely
and regular antibody screening may be discontinued [3].
HLA genotyping is also useful in the risk evaluation for CD
in 1st degree relatives of patients with CD [14].
In conclusion, we report the development of positive
serology for CD in an asymptomatic child with growth re-
tardation, who previously was evaluated for CD and had
resulted negative. Therefore, when faced with retarded
growth in young patients, the paediatric endocrinologist
should always maintain a high index of suspicion for CD,
even if serological markers are negative. Furthermore, in
some selected cases with failure to thrive and negative ser-
ology for CD, after the exclusion of other malabsorption
conditions, the paediatrician could request HLA genotyp-
ing, before the intestinal biopsy, in order to check for the
presence of risk alleles.
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